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A. SPECIFIC AIMS 
Each year diarrhea causes the deaths of over 2.5 million children under age five (1). 
Rotavirus is the single most important etiologic agent of diarrhea world-wide, accounting for 
10-50% of all cases (2-6). In Nicaragua, one of the poorest nations in Latin America, diarrhea 
is the leading cause of mortality of children under age five outside the neonatal period (6). 
Among Nicaraguan children who are hospitalized for severe diarrhea, rotavirus was isolated 
among 28%(7).  
 
In October, 2006, Nicaragua became the first developing world nation to initiate 
universal infant rotavirus immunization (UIRI) with the RotaTeq® vaccine. This live, oral, 
pentavalent human-bovine reassortant vaccine provides 74% protection against any infection 
with the G1, G2, G3 and G4 genotypes*, and provides 98% protection against severe 
infection(8) from these genotypes. Nicaraguan infants now receive this vaccine at the age of 
two, four, and six months as part of the country’s Expanded Program on Immunization. 
Although several other developing world nations have since added the live-attenuated human 
monovalent Rotarix® vaccine to their universal immunization schedules, Rotateq® may prove 
to provide coverage against a broader range of genotypes than Rotarix® (Brazil). Nicaragua 
remains the only developing world nation to use Rotateq® for universal immunization. 
 
The rotavirus vaccine may face challenges to its effectiveness in the developing world. 
Several factors, such as higher rates of breastfeeding, the use of the oral polio vaccine, and 
higher rates of other concomitant gastrointestinal infections have been hypothesized to render 
the rotavirus vaccine less effective. The diversity of genotypes and often inadequate storage 
conditions in the developing world may also limit the vaccine’s effectiveness. 
 
The impact of universal rotavirus immunization on childhood diarrhea in Nicaragua is 
unknown. A clear understanding of the magnitude of the effect of UIRI is important 
information for Nicaragua and other developing world countries who are considering adding 
rotavirus vaccines to their current vaccine armamentarium. Although preliminary research is 
measuring the impact of rotavirus immunization in the hospital setting, virtually nothing is 
known about the effect of UIRI at the primary care or community level. Also, it is not known if 
genotype shift of the virus is occurring, which could limit the future effectiveness of rotavirus 
immunization and would inform needed improvements in the vaccine. Finally, we do not know 
if UIRI is inducing herd immunity. 
  
The purpose of this study is to determine the effect of UIRI on diarrheal disease in 
Nicaragua at the primary care and community levels. Our specific aims are to: 
 
1. Determine the effectiveness of the rotavirus vaccine in primary care clinical 
practice, using a case-control study. 
Hypothesis: We expect that UIRI with Rotateq® will have a vaccine effectiveness of 
about 75% in reducing rotavirus infections that present to primary care centers.  
 
2. Determine the effect of UIRI on diarrhea incidence at the community level, using an 
existing population-based surveillance system. We will compare incidences prior to 
UIRI to incidences following UIRI separately for children who did and did not receive 
the immunization.   
                                                 
*
 Although typing of rotavirus may be done by serologic or genetic analysis, for simplicity, 
rotavirus strain will be referred to as “genotypes”. 
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Hypothesis:  Prior hospital-based studies would lead us to expect a one-third reduction in 
diarrhea incidence among immunized children at the community level. We expect this 
reduction to be most pronounced during the dry season, when the incidence of rotavirus 
infection is higher. We expect to find a modest, but measurable reduction in incidence 
among unimmunized children. 
 
3. Explore if circulating genotypes of the virus have changed following UIRI. We will 
compare the distribution of rotavirus genotypes prior to UIRI with the distribution 
following UIRI. 
Hypothesis: We expect to find a higher percentage of genotypes not covered by the 
Rotateq® vaccine among immunized children who subsequently develop rotavirus 









































B. BACKGROUND AND SIGNIFICANCE 
I. Rotavirus infection causes a high burden of disease in the developing world. 
 
Among all infectious causes of diarrhea, rotavirus is the single most important world-
wide, accounting for 10-50% of all diarrhea cases (2-5). In the United States, rotavirus 
causes 3 million episodes of diarrheal illness, 60,000 to 70,000 hospitalizations, and 20 to 
40 deaths each year(9) (10). In the developing world, poor baseline nutrition and limited 
medical services to adequately treat dehydration cause a much higher toll from rotavirus, 
with an estimated 0.5 million deaths of children under age five from rotavirus annually(11). 
World-wide, there are an estimated 138 million cases of rotavirus diarrhea; 15 to 20% of 
these cases require treatment at a clinic and 1 to 3% require hospitalization (12). Also, in the 
developing world, rotavirus transmission occurs at an earlier age, when children may be 
more vulnerable to dehydration and malnutrition; in a cohort study in Nicaragua, by one year 
of age, 90% of children had developed rotavirus diarrhea or had evidence of 
seroconversion(13). 
 
While the introduction of oral rehydration solution has decreased mortality from 
diarrhea over the past several decades, the morbidity from diarrhea has not followed 
this trend: the incidence of diarrhea today is not lower than the incidence recorded in the 
1950’s (1). Interestingly, in Mexico, improvements in the water supply resulted in a reduced 
incidence of some infectious diarrheas that peak during the rainy season, however, rotavirus 
diarrhea, that peaks during dry season did not decline(14). More alarming is recent evidence 
that early childhood diarrhea results not only in physical growth delays, but also in 
developmental delays, such as decreased cognitive development and impaired school 
performance(15)(16). These long-lasting effects of diarrhea have resulted in a call to adjust 
the disability-adjusted life years (DALYs) weight attributed to diarrheal disease(17,18). 
 
II. Vaccines to prevent rotavirus infection are now available. 
 
In 2006, two new vaccines were introduced for the prevention of rotavirus diarrhea, 
Rotateq® and Rotarix®. Rotateq® (Merck) is a live pentavalent (G1, G2, G3, G4, and P[8]) 
human–bovine (WC3) reassortant rotavirus vaccine, which is currently licensed in the United 
States(8). Rotarix® (Glaxo-Smith-Kline) is a live-attenuated human rotavirus, with G1P[8] 
specificity(19). Both vaccines underwent very large clinical trials of their efficacy and safety 
due to the potential increased risk of intussusception discovered after licensing of a previous 
rotavirus vaccine, RotaShield® (20-23). Both oral vaccines are thought to work by inducing 
a protective IgA immune response induced in the intestines, however, while Rotateq® 
produces genotype-specific immunity, Rotarix® works by invoking a heterotypic 
immune response.  
 
The efficacy and safety of both vaccines were demonstrated in large, double-blind, 
placebo controlled trials. The Rotateq® trials took place primarily in Europe and the US, 
but also included sites in Costa Rica and Guatemala. Immunization with Rotateq® reduced 
hospitalization or emergency department visits for G1, G2, G3, G4, G9, or G12 rotavirus 
infection by between 88 and 100%. The reduction of clinically apparent rotavirus diarrhea of 
any severity was less dramatic. For example, Rotateq® protected against 75% of any 
rotavirus diarrhea of the G1 genotype, 63% of G2 infections, 83% of G3 infections, 48% of 
G4 infections, and 65% of G9 infections(8). The Rotarix® trails included infants from Finland 
and Latin America. After receiving the full course of vaccination, Rotarix® protected against 
severe rotavirus diarrhea and hospitalization for rotavirus diarrhea by 85% (p<0.001). 
However, while Rotarix® protected against approximately 90% of severe rotavirus diarrhea 
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with G1P[8], G3P[8], G4P[8], or G9P[8] genotypes, it protected against only 41% of severe 
diarrhea with the G2P[4] genotype(19). Neither trial found an increased risk of 
intussusception among those receiving the vaccine.  
 
It is unknown how well Rotateq® would protect against genotypes not included in the 
vaccine, such as G5, G8, G9, and P[6]. The inclusion of one P antigen (P[8]) in Rotateq® 
may provide some degree of protection against a G-type that is not included in the vaccine, 
if it is paired with P[8]. However, the G9P[6] and G8P[6] genotypes do not share either a G-
type or P-type with those included in the vaccine. Similarly, we do not know how well the 
heterotypic response of Rotarix® works against a range of genotypes not reported in the 
efficacy trial. It is thought that the Rotarix® may not be effective against the short-
electropherotype strains, such as G9P[6] that belong to a different genogroup as the 
Rotarix® strain, and share fewer antigens(24). 
 
In addition, we do not know how well the vaccines prevent less severe forms of 
diarrhea. The primary end-point in both efficacy studies included the most severe forms of 
rotavirus diarrhea that typically require hospital admission. However, we know little about the 
effect of these vaccines on reducing outpatient visits, which consume limited health care 
resources available in the developing world. Even less is known about the effect of rotavirus 
immunization on the community level, where repeated milder episodes of diarrhea may 
result in physical and developmental delays of children.  
 
III. In the developing world, there are unique challenges to rotavirus vaccine 
effectiveness. 
 
There are concerns that the rotavirus vaccine may not perform as well in developing 
world populations (25). For example, 1) it is unclear how well the vaccines protect against 
the diversity of strains present in the developing world, 2) malnutrition might blunt the 
immune response to the vaccine, 3) breastfeeding may interfere with the immune response, 
4) the oral polio vaccine or other enteric infections may interfere with the immune response, 
and 5) lack of an adequate “cold chain” may decrease effectiveness. Although it is 
encouraging that the Rotarix® vaccine was found to be efficacious in several Latin American 
countries during clinical trials, there may be differences between the study population and 
the general population in these countries. Also, the integrity of the cold chain may be better 
under study conditions than in routine use. 
 
It is unknown whether the rotavirus vaccines will protect against the diverse 
distribution of rotavirus genotypes present in the developing world. A surprising 
diversity of rotavirus genotypes world-wide has been found in the developing world due to 
improved laboratory methods and increased surveillance. G-genotyping is based on the VP7 
antigen in the outer capsid; VP7 plays an important role in immunity against rotavirus In the 
1990’s, 7 different G-types of human rotavirus were defined: G1, G2, G3, G4 were 
considered the most common and G8, G9, G12 were considered to be rare (26-29). Since 
that time, characterization of genotypes has been facilitated by new laboratory methods, 
including RT-PCR genotyping and automated nucleotide sequencing (24). Also, another 
important immune target, the VP4 antigen (“P”), was recognized and is now included in the 
binary classification system of rotavirus.  Finally, the introduction of rotavirus vaccines 
prompted surveillance for rotavirus genotypes in the developing world. These circumstances 
have led to the recognition of 10 G-serotypes of human rotavirus and 11 P-genotypes, which 
are present in 42 different combinations (24). Examples of this increased diversity include: 
10% of rotavirus diarrhea in Brazil is of the G5P[8] genotype(30), 42% of rotavirus diarrhea 
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in Malawi is G6P[8](31), and 24% of rotavirus diarrhea in India is G9P[6](32). There are also 
more mixed rotavirus infections, or, infections with two different rotavirus genotypes, in the 
developing world (32,24). In Nicaragua, Espinoza, et al, characterized 265 rotavirus-positive 
samples collected over a three year period(33) (See Table 1.) Of note, the authors 
subsequently tested the “non-typable” strains for the G9 genotype, and found that G9 





This increased diversity of rotavirus serotypes in the developing world may be attributed to 
the inherent high frequency of reassortment of RNA segments of rotavirus during dual 
infection(34).The higher rate of mixed infection(24) and possibly, higher rates of co-infection 
with non-human strains (35) in the developing world may be the mechanism behind this 
increased diversity. 
 
It is unclear how well the rotavirus vaccines will function amidst this high strain diversity. 
Some concern is raised by recent findings from the pneumococcal immunization program 
among Alaska native children, who had a higher frequency of non-covered strains prior to 
the immunization program. Three years after the introduction of the vaccine program, there 
was an increase in the disease rate of nonvaccine serotypes by 140% in comparison with 
the pre-vaccine era (36).  Also, in Brazil there is early evidence that in a population with a 
Rotarix immunization program, there was a predominance of G2P[4] strains which are not 
covered by the vaccine(37).  
 
Malnutrition (38) and vitamin A deficiency(39) impair immunity and increase 
susceptibility to natural rotavirus diarrhea, which raises concerns about the immune 
response to rotavirus vaccines in malnourished infants. Malnutrition has been shown to 
decrease the immune response to other vaccines.  Although the antibody levels were the 
same, antibody affinity to tetanus toxoid was decreased in malnourished children (40). Also, 
hemodialysis patients with malnutrition had decreased immunity following immunization with 
hepatitis B(41). On the other hand, studies examining the effect of malnutrition on the 
immune response to the measles vaccine, also a live vaccine, show little effect of 
malnutrition(42)(43). Recently, one study showed that the efficacy of the Rotarix® vaccine 
was the same in malnourished children as in children with normal nutrition (44); however, 
evidence on Rotateq® is lacking.  
 
(From Espinoza, 2006) 
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Breastmilk can interfere with the immune response to either natural infection or 
immunization (45); IgA in breast milk may bind to the rotavirus vaccine and thereby blunt 
the immune response and tryspins present in breast milk may physically destroy the 
vaccine. In addition, there is evidence that lactadherin, a 46 kDa glycoprotein, specifically 
binds to rotavirus, suggesting another mode for interference with a live rotavirus vaccine 
(46). In the developing world, rates of breastfeeding are typically higher than in the 
industrialized world, and breast milk IgA titers for rotavirus may be higher in developing 
world populations. Several small studies have compared the efficacy of rotavirus vaccine 
candidates in breast-fed and formula-fed infants. A meta-analysis in 1990 showed that the 
immune response to rotavirus vaccine candidates was decreased among breastfed infants 
(47). A subsequent study in 1995 showed no difference among the two feeding groups (48). 
To date, there are no published studies on the effect of breastfeeding with the two currently 
licensed vaccines. 
 
Another concern is that co-administration of a rotavirus vaccine with the oral polio 
vaccine may diminish the immune response to either one of the two vaccines. Studies 
with past vaccine candidates have addressed this concern and have found either no effect 
or a small effect on immune response when these two, live, oral vaccines are co-
administered (49,50). There is some evidence from Brazil with Rotarix® that it does not 
interfere with the immune response to OPV (51), however, evidence on Rotateq® is lacking. 
Similarly, there is the concern is that enteric infections, with other enteric viruses, bacterial 
pathogens, and intestinal parasites may interfere with the immune response to the rotavirus 
vaccine. Enteric infections are clearly more prevalent in the developing world. However, 
there are no published studies that examine the link between these other enteric infections 
and the immune response to the rotavirus vaccine. 
 
Finally, vaccine storage requirements may present a problem to rotavirus vaccine 
effectivness in the developing world. Both rotavirus vaccines must be protected from light 
and refrigerated at 2-8°C until used. Electricity outages and lack of adequate refrigeration 
equipment during transport and storage of the vaccine present a significant challenge. 
 
IV. Nicaragua’s Universal Infant Rotavirus Immunization Program (UIRI) offers a 
unique opportunity to study vaccine effectiveness. 
 
In October, 2006, Nicaragua became one of the first developing world countries to 
add a rotavirus vaccine to the country’s Expanded Program on Immunization 
schedule. Now Nicaraguan children receive a dose of the Rotateq® vaccine at ages 2, 4, 
and 6 months. This arrangement for free Rotateq® vaccine was facilitated between Merck 
and the Nicaraguan Ministry of Health by President Clinton’s Millenium Vaccine Initiative. 
While several other Latin American countries have since added Rotarix® to their national 
vaccine schedules, due to its lower cost and availability through the Global Alliance for 
Vaccines and Immunization (GAVI), Nicaragua is the only developing world nation to use 
Rotateq®.  
 
Studying Rotateq® vaccine’s effectiveness provides needed information for 
Nicaragua as well as other developing world countries who are considering adding a 
rotavirus vaccine to their current immunization schedules. Studying Nicaragua’s UIRI 
program gives insight on whether the rotavirus vaccine that produces genotype-specific 
immunity is effective. There is some limited evidence from Brazil (37) that Rotarix®, which 
works by invoking a heterotypic immune response, may not be effective against the diversity 
of rotavirus serotypes in the developing world.  
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Our collaborators at the Centers for Disease Control (CDC) are beginning to evaluate 
Nicaragua’s UIRI program at several hospitals in Nicaragua, however the program’s 
effect on the primary care and community level remain unknown. Measuring the 
vaccine’s effectiveness in the hospital setting is important for understanding the most severe 
forms of rotavirus infection that present to the health care system. However, for each case of 
rotavirus diarrhea that requires hospitalization, there are approximately 20 cases that 
require a visit to the primary care clinic, and 80 cases in the community that never receive 
standard medical care. Our increased understanding of the physical and developmental 
sequelae of diarrhea episodes to the child, and the economic costs of diarrhea to developing 
nation’s strained health care budgets require that we understand the effect of UIRI on the 
entire spectrum of diarrhea, including the primary care and community levels. Finally, 
studying the community effect of the vaccine in both unimmunized and immunized family 







































C: PRELIMINARY DATA: 
 
 Prevalence of rotavirus diarrhea among children presenting to primary care and 
hospital settings in Leon prior to UIRI.  
In Espinoza, et al’s study(7), 296 children between age 3 and 36 months who presented 
to primary care centers and hospitals in Leon with diarrhea received ELISA testing for 
rotavirus. 28% of these children tested positive for rotavirus. 
  
 Prevalence of rotavirus diarrhea among children presenting to primary care in 
Leon following UIRI. (Study is funded by the Gorgas Memorial Institute Research 
Award, PI: Sylvia Becker-Dreps, $25,000, awarded 10/07). We are currently measuring 
the prevalence of rotavirus diarrhea among children under 36 months of age who 
present with diarrhea to six primary care centers in Leon. Our goal is to compare the 
prevalence of rotavirus among children presenting with diarrhea before UIRI to the 
prevalence following UIRI. Our preliminary data of our first 90 participants, recruited in 
April and May, 2008 show a rotavirus prevalence of 5.6%. In addition to the study of 
rotavirus prevalence, we are currently piloting specific aim 1 in Leon, including piloting 
our questionnaire and our informed consent procedures. Our trained home interviewers 
are piloting recruitment and questionnaire administration to community controls. We 
have received IRB approval for specific aims 1 and 3 from both the institutional review 
board at the University of North Carolina-Chapel Hill and the biomedical ethics 
committee at the University of Nicaragua-Leon. 
 
 Distribution of rotavirus serotypes prior to UIRI. Between 2001 and 2003, 
Espinoza(33), et al, determined the serotypes of rotavirus among 265 rotavirus positive 
samples collected in children under age 3 (Table 1, above). These data will be used to 
compare to the distribution of serotypes following UIRI among the rotavirus-positive 
samples collected in specific aim 1. 
 
 Hospital-based data on prevalence of rotavirus among children presenting with 
diarrhea (CDC). Our collaborators at the CDC are currently conducting surveillance at 
five public hospitals throughout Nicaragua to determine the prevalence of rotavirus 
among children under age 36 months presenting with diarrhea. This study started in 
January, 2008, and will continue into early 2009. These hospital-based data should 
complement the findings at primary care and community levels. 
 
 Diarrhea incidence among children under age 5 using a community sample. Using 
the existing population-based surveillance system in Leon, Nicaragua from 2001-2003, 
the incidence of diarrhea of any cause was determined for both the dry season (0.0716 
episodes per person-month) and the rainy season (0.0902 episodes per person-month). 
This incidence was obtained from a random sample of 640 children under age 5 who live 
in a total of 414 households. Home interviewers visited the children every two weeks 
during the dry (December to March) and the rainy (July to November) seasons. 
Information collected included household characteristics, family structure, access to 
health services, self-medication, parental information, breastfeeding history, diarrhea 
episodes and their characteristics in the past 14 days. This data will serve the basis for 





D. RESEARCH DESIGN AND METHODS: 
  
Specific Aim 1: Determine the effectiveness of the rotavirus vaccine in primary care 
clinical practice, using a case-control study. 
 
To determine the effectiveness of the vaccine in clinical practice, we will perform a case-
control study of patients presenting to six community health facilities with severe diarrhea due 
to rotavirus infection, using both community and clinic-based controls. Cases will be children 
aged 3 to 36 months who present with severe diarrhea, defined as three or more liquid stools 
within the past 24 hours and whose stool samples are confirmed by ELISA to have rotavirus. 
Cases will be recruited from six government-administered outpatient health centers in León. 
These health centers are free, conveniently located, and are widely attended by residents of 
each neighborhood. We are already working with these six health centers to determine the 
new prevalence of rotavirus among children presenting with diarrhea. Study nurses will collect 
stool samples or soiled diapers from each of the potential cases (children aged 3 to 36 months 
presenting with severe diarrhea) and also administer a questionnaire to the parents. 
 
For each true case who is rotavirus-positive by ELISA, one community control and one clinic 
control will be chosen. Community controls will be chosen from households in the same 
community as the case by home interviewers. They will start at the home of the case and then 
approach households on alternating (clockwise and counterclockwise) sides until a child within 
one month of age of the case is found. Clinic controls will be chosen among children within 
one month of age of the case presenting to the same clinic with diarrhea, but whose ELISA 
testing is negative for rotavirus. 
 
Inclusion criteria for cases:  
 Child presents to primary care clinic for assessment of diarrhea, defined as three 
episodes within a 24 hour period 
 Child was born on or after August 15, 2006 (the earliest date of birth to be eligible 
to receive the rotavirus vaccine when UIRI started in October, 2006) and is 
currently at least 10 weeks of age  
 Child has not had diarrhea for more than 14 days and was not admitted to the 
hospital for this episode of diarrhea 
 Father or mother gives permission for the child to participate in the study and have 
signed the informed consent form 
 CHILD’S STOOL SAMPLE IS POSITIVE FOR ROTAVIRUS BY ELISA TESTING 
 
Inclusion criteria for clinic controls: 
 Inclusion criteria are the same as for cases, (above) except: CHILD’S STOOL 
SAMPLE IS NEGATIVE FOR ROTAVIRUS BY ELISA TESTING 
 Child is within one month of age of the case (except the lower age limit remains 10 
weeks old) 
 
Inclusion criteria for community controls: 
 Child is within one month of age of the case (except lower age limit remains 10 
weeks old) 
 Child is identified by starting at the house of the case, and then approaching 
houses on alternating (clockwise and then counterclockwise) sides of the street 
 Father or mother gives permission for the child to participate in the study and have 
signed the informed consent form 
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The questionnaire for both cases and controls includes each patient’s date of birth, rotavirus 
immunization history from the child’s immunization card or medical chart (including number of 
doses and date of immunization), oral polio vaccine history, detailed breastfeeding history, 
maternal educational attainment, household water source and sanitation system. Nurses or 
home interviewers will also measure the child’s weight and height in order to determine his or 
her nutritional status. From our current experience with recruitment from the same health 
facilities, we can expect that the data collection will take place between July, 2009 and June, 
2010. All of the children in the study will have been born on or after September, 2006, and 
would be eligible for rotavirus immunization. These ages were chosen to capture the 
childhood period when most children in Nicaragua acquire their first and most severe rotavirus 
infection (13). ELISA testing will be performed in Dr. Espinoza’s virology laboratory at the 
University of Nicaragua-León, using a commercial kit (DAKO), which has a sensitivity of 
98.0% and specificity of 97.2% (52). A sample size of 120 matched pairs will provide at least 
80% power to detect a significant effect of the vaccine if the true odds ratio is 0.25 or less 
(two-sided alpha=0.05), 20% of pairs are discordant for vaccine status, and complete vaccine 
data are available for at least 83% of the matched pairs (nQuery version 6.0).   
 
Statistical analysis: Using the age-matched pairs, we will calculate the Mantel-Haenszel 
estimate of the odds ratio along with a 95% confidence interval for severe diarrhea for the 
immunized versus non-immunized children. The analysis will be performed separately using 
community controls and clinic-based controls. We will also perform a sensitivity analysis to 
account for the possible misclassification due to the sensitivity and specificity of the ELISA 
testing. Vaccine effectiveness will be calculated as 1 minus the odds ratio. We will also 
compare the overall frequency of rotavirus among the potential cases to a study done at the 
same health centers prior to UIRI (7). For our secondary aim, we will use Chi-square testing to 
compare the frequency of rotavirus diarrhea among immunized children who have and do not 
have each potential risk factor (breastfed, received OPV, malnourished, inadequate water 
source and inadequate sanitation system). We will also perform logistic regression to calculate 
the ORs for rotavirus diarrhea for each of the potential risk factors of interest.  
 
 
Specific Aim 2: Determine the effect of UIRI on diarrhea incidence at the community 
level, using an existing population-based surveillance system. We will compare 
incidences separately for children who did and did not receive the immunization.   
 
To estimate the impact of UIRI on a population level, we will evaluate changes in diarrhea 
incidence and diarrhea-related mortality using an existing population-based surveillance 
system in León. The Center for Demographic and Health Research (Centro de Investigación 
en Demografía y Salud, or CIDS) established in 1993 provides longitudinal prospective 
epidemiological surveillance for the municipality of León (total estimated population: 200,000). 
CIDS was established in order to accurately measure child mortality rates and causes in León, 
Nicaragua. It is the only surveillance system in Latin America to be a member of the IN-










Between 2001 and 2003, prior to the 
initiation of UIRI, CIDS collected data on 
diarrhea episodes among 640 children 
under age 5. These children were chosen 
randomly using the population-based 
surveillance system. Skilled female field 
workers interviewed the mother of the 
child, or the person who was responsible 
for the child if the parents were not at 
home. The data collection occurred every 
two weeks during 14 weeks of the dry 
season (December to March) and 20 
weeks of the wet season (July to 
November) each year. This bimodal 
distribution of diarrhea cases can be seen 
in ministry of health data collected from all primary care centers and hospitals in Nicaragua 
(See Figure 1, above). 
 
In addition to diarrhea episodes within the past 2 weeks, field workers collected information on 
diarrhea characteristics, socioeconomic status, breastfeeding history, household water 
source, sanitation system, self-medication, and access to health services. Of the 640 children 
in the study, 216 children were found to have diarrhea. The incidence rate was 0.07 per 
person-month during the dry season, and 0.09 per person-month during the wet season 
(unpublished data). 
 
We will now recalculate the incidence of diarrhea after UIRI, from 2009 to 2011. We will use 
similar methods, including home visits every 2 weeks to children chosen randomly from the 
population-based surveillance system in Leon. In addition to the previous data collected, we 
will now include rotavirus immunization history. This will allow us not only to determine the 
new incidence of diarrhea following UIRI in the community, but will also allow us to determine 
whether the incidence is different among children who did not receive the immunization, a 
gauge of indirect effects of the immunization (herd immunity). One limitation of the study is 
that there may be other factors responsible for the change in diarrhea incidence between 
these two time periods. To address this, we will assess for confounding using data on 
household water source, sanitation system, breastfeeding history, and socioeconomic status. 
 
Statistical Analysis/Sample Size- Using a simulation study, we calculated that a sample size of 
640 children, living in approximately 414 households, will have a power of 0.84 for detecting a 
30% reduction in all-cause diarrhea among children following UIRI. This is among children 
who are of the age group that is eligible to receive the rotavirus vaccine. We will use Poisson 
regression (with robust variance estimation) to estimate the rate ratios and the 95% 
confidence intervals for the effect of UIRI among children eligible for the rotavirus vaccine. 
Similarly, we will also compare the diarrhea incidence among children who were not eligible 
for the vaccine (those whose birthdays are before August, 2006, and therefore were too old 
when UIRI was implemented) before and after UIRI. This would be one measure the indirect 
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Specific Aim 3: Characterize the circulating genotypes of the virus following UIRI. 
 
Using the rotavirus-positive samples collected in Specific Aim 1, we will determine the 
distribution of genotypes present among groups of both immunized and unimmunized 
children. G and P antigens are carried by outer capsid proteins and both are believed to be 
responsible for the development of protective immunity. A study (33) conducted in Nicaragua 
between 2001 and 2003 described the distribution of G (G1-G4) and P (P4,P6, P8) genotypes 
prior to UIRI (See table 1 in preliminary data section). We will test for these strains and also 
the newly emergent G5, G8, and G9 strains. We will analyze rotavirus-positive samples by 
RT-PCR, using a microarray-based system described by Lovmar (54) (See Figure 5 below). 
This method uses multiplex capture and type-specific extension on microarrays to efficiently 
genotype a large number of samples with a high degree of polymorphism. 
 
Statistical analysis: We will report the distribution of genotypes among the entire sample, and 
then separately for the groups of immunized and unimmunized children. We will then use the 
extension of the Fisher’s exact test to compare this distribution of genotypes to those found 
prior to UIRI (33). 
 
Figure 5: RT-PCR Microarray system 
 
 
Principle and steps of the microarray procedure for genotyping of HRV. Sets of capture oligonucleotides (oligos) specific for the 
G and P types of HRV are covalently immobilized on glass microscope slides (A). With these oligonucleotides as probes, the 
RT-PCR products containing type-specific regions of the VP7 and VP4 genes are captured on the microarrays by hybridization 
under low-stringency conditions (B). Oligonucleotides with 3′ ends that are matched to the sequences of the captured 
templates are extended with a mixture of deoxynucleoside triphosphates containing cyanine 5 (Cy5)-labeled dUTP by using a 
thermostable DNA polymerase (C). The fluorescence incorporated in the sequence-specific primer extension reaction is 
measured in a microarray scanner (D). The results are interpreted by visual inspection of the arrays or by calculation of the 








ADDENDUM: ADDITIONAL BACKGROUND ON ROTAVIRUS  
 
The virus 
Rotaviruses are double-stranded RNA viruses which are transmitted by the fecal-oral route 
(55). The high transmissibility of rotavirus may be explained by two factors: 1) the high level of 
viral shedding and 2) the persistence of the virus in the environment. During the most 
infectious period, 2-5 days after onset of diarrhea, as many as 1010 viral particles are released 
per gram of stool (56). Among children hospitalized for rotavirus diarrhea, viral shedding 
extended to 57 days after the onset of symptoms, with a median of 10 days (57). At the same 
time, the infectious dose needed to cause rotavirus is low (58). Rotaviruses are very persistent 
in the environment, surviving for about four hours on human hands.  When on fomites, they 
favor low humidity, surviving for several days if the relative humidity is less than 50%. In water 
sources, they can remain infectivity for weeks. Rotaviruses are somewhat resistant to 
commonly used hard-surface disinfectants (39,59). 
 
Infection is characterized by watery diarrhea, vomiting, fever, and dehydration (60). Diarrhea 
lasts an average of 5 days, although first infections and infections in immunocompromised 
children may be more prolonged (56). Bloody diarrhea is uncommon, and there are no fecal 
leukocytes on stool examination (34). Dehydration is more common with rotavirus as 
compared with diarrhea from other causes (60). Untreated dehydration, especially in infants 
and young children, may lead to death.  
 
Rotaviruses are divided into seven distinct groups (A to G); groups A, B, and C are found in 
humans, with group A being the most common (34). Within each group, rotaviruses are 
classified by a binary system (similar to influenza) based on its VP7 outer capsid protein 
(“G”) and by its VP4 outer capsid protein (“P”). 
 
The epidemiology of rotavirus  
In the United States, rotavirus causes 3 million episodes of diarrheal illness, 60,000 to 
70,000 hospitalizations, and 20 to 40 deaths each year (9,10). In the developing world, poor 
baseline nutrition and limited medical services to adequately treat dehydration cause a much 
higher toll from rotavirus, with an estimated 600,000 deaths from rotavirus annually (11). 
Transmission occurs at an early age in developing countries; in a cohort study in Nicaragua, 
by one year of age, 90% of children developed rotavirus diarrhea or had evidence of 
seroconversion(13).  
 
In temperate climates, rotavirus infection follows an unexplained seasonal pattern, with 
peaks occurring in the winter (56). This may be explained by rotavirus’ persistence at low 
relative humidity. In tropical climates, rotavirus does not follow a strict seasonal pattern, but 
cases occur throughout the year (61). Data from Nicaragua endorse this pattern of year-
round transmission, however two yearly peaks are typically seen during the dry season 











Figure 1.  
Monthly distribution of rotavirus-positive diarrhea among a cohort of 235 children in 
Nicaragua 
 
(From Espinoza,  
 
The most common circulating genotypes of rotavirus world-wide are G1,G2,G3, and G4. In 
Nicaragua, rotavirus-positive samples collected over a three year period were characterized 
(33).  Recently, G5 and G8 genotypes were recognized in Latin America and G9 serotypes 
have emerged globally.  
 
Interestingly, the most prevalent genotype in the population varies from year to year; it is 
unlikely that the same G-type would predominate for two years in a row. For example, the 
same Nicaraguan study done over three years found that a G2 strain was most prevalent 
during the first year, a G1 strain was most prevalent during the second year, and G3 was 
most prevalent in the third year (33). 
 
 Laboratory diagnosis and genotype characterization of Rotavirus 
In the typical clinical setting, rotavirus testing is often not performed, because it would not 
alter the course of treatment, which is primarily rehydration. Under limited clinical settings 
and for research purposes, stool ELISAs for rotavirus are an effective diagnostic test. The 
most commonly used ELISA tests for the VP6 inner capsid protein. Sensitivity of ELISA is 
best between the first and fourth day after the onset of symptoms. The sensitivity of 
commonly used commercial ELISA kits are over 95% (52). Reverse Transcriptase-PCR (RT-
PCR) can detect viral shedding even after diarrhea has resolved (56). Other diagnostics 
used primarily for research or in limited clinical settings include dot hybridization, electron 
microscopy, cell culture, and testing for serologic response with complement fixation. 
 
Serotypic or genotypic characterization of circulating rotaviruses is important to determine if 
the vaccine being used will be effective in the population, and to determine if a shift in strains 
is occurring after introduction of UIRI. Determination of G-types can be done either with 
either ELISA testing or RT-PCR which have a complete concordance rate (34). 
(From Espinoza, 1997b) 
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Determination of P-types is only possible with RT-PCR. RT-PCR of both G- and P-types can 
be done efficiently with microarray-based system (54), which allows for the genotyping of a 
high volume of rotavirus samples with a high degree of polymorphism.  
 
Vaccines for prevention of rotavirus,  Rotateq® and Rotarix® 
The Rotateq® vaccine underwent a double-blind, placebo controlled trial of 68,038 infants. 
The trials took place primarily in Europe and the US, but also included sites in Taiwan, Costa 
Rica, and Guatemala.  After the first full rotavirus season after administration, Rotateq® 
protected against any G1-G4 rotavirus infection by 74% (95% CI 67%, 80%) and protected 
against hospitalizations for G1-G4 rotavirus infection by 94.5% (95% CI, 91%, 97% 
percent)(8).  The Rotarix® trails included 63,225 infants from Finland and Latin America. 
Rotarix® protected against hospitalization for any rotavirus by 85% (p<0.001)(19). Neither 
trial found an increased risk of intussusception among those receiving the vaccine. Of note, 
neither trial included sites in Africa or Asia, except for Taiwan. 
 
There are some important differences in the storing and dosing of the two vaccines. 
Rotateq® is supplied as a pre-mixed solution that must be protected from light and kept 
refrigerated (at 2-8°C) until it is used. Rotarix® is stored as a powder that is reconstituted 
with a solvent. The solvent can be stored at ambient temperature; the powder needs to be 
protected from light and is ideally refrigerated (at 2°C to 8°C), however, it is known to be 
stable when stored at 37°C for 1 week. While Rotateq® requires three doses of vaccine, 
Rotarix® requires only two doses (8)(19). 
 
In October, 2006, Nicaragua became one of the first developing world countries to add the 
rotavirus vaccine to the country’s Expanded Program on Immunization schedule. Now 
Nicaraguan children at age 2, 4, and 6 months receive a dose of the Rotateq® vaccine. 
 
Determining vaccine effectiveness on a population level 
Several approaches in determining vaccine effectiveness that have been used in the past 
include: 1) Compare infection rates in the era after immunization to historical controls, for 
example, using hospital or laboratory data (62)  2) establish an active surveillance system to 
detect cases in the years prior to the introduction and compare these to the cases in the 
years following introduction (63), 3) Perform a case-control study to compare immunization 
rates in cases as compared to controls; cases can be population-based or health facility-
based(64), or 4) create a mathematical model to predict that effect on the infection(65), 5) 
Perform a randomized controlled trial for effectiveness(66). 
  
Using a case-control design allows one to calculate the matched odds ratio for immunization 
among the cases vs. the controls. One can then calculate the vaccine effectiveness: 
  
Vaccine effectiveness (%) = 1 - matched OR for immunization  
 
Haber (67) describes a new measure, the population vaccine effectiveness, which more 
closely approximates a vaccine’s effectiveness in a population by including the indirect 
effects (herd immunity) associated with the immunization in that population.  
To determine these herd immunity effects, an active surveillance system which examines 
infection rates among the unvaccinated population could be used, as in Figure 2 below for 
the PCV7 vaccine (68). If there is a range of immunization coverage in the surveillance area, 
one can use the different coverage rates in different geographic areas to determine what rate 




                                                                                      (MMWR, 2005) 
 
Genotypic characterization before and after introduction of the rotavirus vaccine 
Characterizing the genotypes of rotavirus before vaccine introduction is essential to 
determine if the vaccine will be effective in this population. Namely, a high frequency of G5, 
G8, or G9-type infections in the population would indicate that the vaccine may not be 
effective. Characterizing the genotypes following immunization allows us to determine if 
genotypic shift is occurring. From the available literature, this has never been described in a 
vaccine against a virus. However, in the case of the PCV7 vaccine, there is evidence of an 
increased risk of infection of non-vaccine pneumococcus serotypes in immunized individuals 
(36). If replacement with non-vaccine serotypes is truly occurring, the immunization’s 
effectiveness in the future could be undermined. 
 
APPLICATION OF STUDY RESULTS/CONCLUSION 
By quantifying the impact of Nicaragua’s rotavirus immunization program, this study could 
provide important information for Nicaragua as well as other developing world countries who 
are considering adding the rotavirus vaccine to their current immunization schedules. 
Although vaccines have a high priority on the global health agenda, this is not a decision to 
be taken lightly in resource-poor countries. A complete course of Rotateq® costs $198.56 
(US dollars) per child, which may consume the entire health budget in some countries. In the 
future, we would like to use this data as the basis of a cost-effectiveness analysis. Especially 
in resource-poor countries, policy makers need to make evidence-based decisions to make 
the best use of their limited healthcare funds. We hope that this study would help provide 
these policy makers with some of the evidence they need to decide on whether to implement 
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